Compare CNNE & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNNE | LXRX |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.0M | 703.3M |
| IPO Year | 2017 | 2000 |
| Metric | CNNE | LXRX |
|---|---|---|
| Price | $14.68 | $2.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $20.25 | $4.15 |
| AVG Volume (30 Days) | 445.9K | ★ 4.6M |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | ★ 4.47% | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $499,700,000.00 | $49,803,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.37 | ★ 60.24 |
| 52 Week Low | $10.46 | $1.00 |
| 52 Week High | $21.96 | $2.68 |
| Indicator | CNNE | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.87 | 50.82 |
| Support Level | $13.83 | $1.50 |
| Resistance Level | $14.99 | $2.61 |
| Average True Range (ATR) | 0.45 | 0.16 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 87.01 | 31.65 |
Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.